Glaucoma Treatment Via Intracameral Ocular Implants

A method for lowering intraocular pressure in a subject in need thereof, comprising:

• administering at least one intracameral implant to the anterior chamber of said subject's eye,
• wherein said intracameral implant comprises a biodegradable polymer matrix and at least one therapeutic agent homogenously dispersed therein,
• wherein said intracameral implant achieves a sustained release of said therapeutic agent into the aqueous humor, and
• wherein said therapeutic agent is released at a concentration below an EC50 calculated for said therapeutic agent when administered without said intracameral implant, and
• whereby the intraocular pressure in said subject's eye is lowered.

A pharmaceutical composition for treating an ocular condition, comprising:

• A) a biodegradable polymer matrix;
• and
• B) at least one therapeutic agent homogenously dispersed within the polymer matrix
• wherein the biodegradable polymer matrix contains a mixture of polymers comprising:
• i) 9+/−5% of ester end-capped biodegradable poly(D,L-lactide-coglycolide) copolymer having an inherent viscosity of 0.8 to 1.2 dL/g measured at 0.1% w/v in CHCl3 at 25° C. with a Ubbelhode size 0c glass capillary viscometer;
• and
• ii) 49+/−5% of ester end-capped biodegradable poly(D,L-lactide) homopolymer having an inherent viscosity of 1.8 to 2.2 dL/g measured at 0.1% w/v in CHCl3 at 25° C. with a Ubbelhode size 0c glass capillary viscometer.